Switch theme
Sign up to access all valuation multiples
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
2012
596
LTM Revenue $27.7M
LTM EBITDA -$228M
$68.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AbCellera has a last 12-month revenue (LTM) of $27.7M and a last 12-month EBITDA of -$228M.
In the most recent fiscal year, AbCellera achieved revenue of $28.8M and an EBITDA of -$204M.
AbCellera expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AbCellera valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $27.7M | XXX | $28.8M | XXX | XXX | XXX |
| Gross Profit | $27.7M | XXX | $28.8M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$228M | XXX | -$204M | XXX | XXX | XXX |
| EBITDA Margin | -825% | XXX | -708% | XXX | XXX | XXX |
| EBIT | -$291M | XXX | -$301M | XXX | XXX | XXX |
| EBIT Margin | -1050% | XXX | -1044% | XXX | XXX | XXX |
| Net Profit | -$178M | XXX | -$163M | XXX | XXX | XXX |
| Net Margin | -642% | XXX | -565% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AbCellera's stock price is $2.
AbCellera has current market cap of $606M, and EV of $68.5M.
See AbCellera trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $68.5M | $606M | XXX | XXX | XXX | XXX | $-0.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AbCellera has market cap of $606M and EV of $68.5M.
AbCellera's trades at 2.4x EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate AbCellera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AbCellera has a P/E ratio of -3.4x.
See valuation multiples for AbCellera and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $606M | XXX | $606M | XXX | XXX | XXX |
| EV (current) | $68.5M | XXX | $68.5M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.4x | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbCellera's last 12 month revenue growth is 33%
AbCellera's revenue per employee in the last FY averaged $48K, while opex per employee averaged $0.6M for the same period.
AbCellera's rule of 40 is -472% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AbCellera's rule of X is -742% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AbCellera and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | -825% | XXX | -708% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -472% | XXX | -675% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -742% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $48K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 580% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1144% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AbCellera acquired XXX companies to date.
Last acquisition by AbCellera was XXXXXXXX, XXXXX XXXXX XXXXXX . AbCellera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AbCellera founded? | AbCellera was founded in 2012. |
| Where is AbCellera headquartered? | AbCellera is headquartered in United States of America. |
| How many employees does AbCellera have? | As of today, AbCellera has 596 employees. |
| Who is the CEO of AbCellera? | AbCellera's CEO is Dr. Carl L.G. Hansen, PhD. |
| Is AbCellera publicy listed? | Yes, AbCellera is a public company listed on NAS. |
| What is the stock symbol of AbCellera? | AbCellera trades under ABCL ticker. |
| When did AbCellera go public? | AbCellera went public in 2020. |
| Who are competitors of AbCellera? | Similar companies to AbCellera include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of AbCellera? | AbCellera's current market cap is $606M |
| What is the current revenue of AbCellera? | AbCellera's last 12 months revenue is $27.7M. |
| What is the current revenue growth of AbCellera? | AbCellera revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of AbCellera? | Current revenue multiple of AbCellera is 2.5x. |
| Is AbCellera profitable? | Yes, AbCellera is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AbCellera? | AbCellera's last 12 months EBITDA is -$228M. |
| What is AbCellera's EBITDA margin? | AbCellera's last 12 months EBITDA margin is -825%. |
| What is the current EV/EBITDA multiple of AbCellera? | Current EBITDA multiple of AbCellera is -0.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
